Photoactivatable ('caged') pharmacological agents have revolutionized neuroscience but the palette of available ligands is limited. We describe a general method for caging tertiary amines using an unconventional quaternary ammonium linkage that is chemically stable and elicits a desirable red-shift in activation wavelength. A photoactivatable nicotine (PA-Nic) prepared using this strategy could be uncaged via 1-or 2-photon excitation, making it useful for optopharmacology experiments to study nicotinic acetylcholine receptors (nAChRs) in different experimental preparations and spatiotemporal scales.. CC-BY-NC-ND 4.0 International license It is made available under a was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/260232 doi: bioRxiv preprint first posted online Feb. 5, 2018; 2 Photoactivatable ('caged') compounds are essential for modern biology and remain the only tools available for modulation of native proteins with high spatiotemporal resolution. The development of new photoactivatable compounds that are chemically stable and activatable with 1-or 2-photon illumination remains an important application of organic chemistry to the biosciences. The ability to uncage ligands for glutamate and γ-aminobutyric acid (GABA) receptors enabled seminal 'optopharmacology' studies on the biophysics and subcellular location of functional proteins within complex biological environments [1][2][3] . Caged ligands targeting other receptors are rare, however, which has prevented precise examination of additional protein classes. We developed a general strategy for preparing photoactivatable drugs through alkylation of tertiary nitrogen atoms to form photolabile quaternary linkages. The resulting photoactivatable nicotine (PA-Nic) exhibits ideal chemical and spectroscopic properties for interrogating endogenous nicotinic acetylcholine receptors (nAChRs) in brain tissue.Many pharmacological agents cannot be caged using standard strategies because they lack obvious attachment sites (e.g., CO 2 H, OH, NH) for photolabile groups. Four examples of 'uncageable' drugs include nAChR agonists nicotine (1) and PNU-282,987 (2), the opioid fentanyl (3), and the selective serotonin reuptake inhibitor escitalopram (4, Fig. 1a). A shared feature of these compounds is a tertiary nitrogen, a common motif in many pharmacological agents. We envisioned a general caging strategy involving covalent attachment of a coumarin [4][5][6] photolabile group to form a quaternary ammonium salt. This approach has been employed by chemists to create photoactivatable tertiary amines including polymer initiators 7 , amino acids 8 , mustards 9 , and tamoxifen 10 , but has never been used in a biological context. We initially applied this strategy to nicotine (1), alkylating with coumarin 5 to yield photoactivatable nicotine (PANic, 6; Fig. 1b). PA-Nic releases nicotine upon UV illumination (365 nm) with a photoch...